
The NVX-CoV2373 vaccine was evaluated in adolescents aged 12 to 17 years.

The NVX-CoV2373 vaccine was evaluated in adolescents aged 12 to 17 years.

The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.

Abigail Donovan, MD, discusses what brexpiprazole can do for treating schizophrenia in older children.